CanSino Biologics wins patent approval for China first COVID-19 vaccine: Report
New Delhi: China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday.
The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug. 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil, and Chile to launch Phase III trials in those countries.
CanSino's Hong Kong shares rose around 14% in Monday's morning session. Its Shanghai shares rose by 6.6% as of midday.
Also Read: Make In US Campaign: Trump's Pharma Executive Order Requires US Govt To Buy Essential Drugs From US Firms
